Cargando…
Long Standing Eculizumab Treatment without Anticoagulant Therapy in High-Risk Thrombogenic Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-orphan disease affecting all hematopoietic cell types. The abnormality of red blood cells in this disease predisposes to intravascular complement-mediated hemolysis. Eculizumab is an orphan drug used to treat this rare disease. Thrombosis is the...
Autores principales: | Al-Jafar, Hassan A., AlDallal, Salma M., Askar, Haifa A., Aljeraiwi, Ali M., Al-Alansari, Ahmad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591499/ https://www.ncbi.nlm.nih.gov/pubmed/26487933 http://dx.doi.org/10.4081/hr.2015.5927 |
Ejemplares similares
-
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009) -
Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
por: Brodsky, Andrés, et al.
Publicado: (2012) -
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
por: Al-Ani, Fatimah, et al.
Publicado: (2016) -
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012) -
Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
por: Fassett, Michael J., et al.
Publicado: (2021)